Formation of resilient biofilms on medical devices colonized by pathogenic microorganisms is a major cause of health-care associated infection. While in vitro biofilm analyses led to promising anti-biofilm approaches, little is known about their translation to in vivo situations and on host contribution to the in vivo dynamics of infections on medical devices. Here we have developed an in vivo model of long-term bacterial biofilm infections in a pediatric totally implantable venous access port (TIVAP) surgically placed in adult rats. Using non-invasive and quantitative bioluminescence, we studied TIVAP contamination by clinically relevant pathogens, Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus and Staphylococcus epidermidis, and we demonstrated that TIVAP bacterial populations display typical biofilm phenotypes. In our study, we showed that immunocompetent rats were able to control the colonization and clear the bloodstream infection except for up to 30% that suffered systemic infection and death whereas none of the immunosuppressed rats survived the infection. Besides, we mimicked some clinically relevant TIVAP associated complications such as port-pocket infection and hematogenous route of colonization. Finally, by assessing an optimized antibiotic lock therapy, we established that our in vivo model enables to assess innovative therapeutic strategies against bacterial biofilm infections.
References
[1]
Hall-Stoodley L, Stoodley P (2009) Evolving concepts in biofilm infections. Cellular Microbiology 11: 1034–1043.
[2]
Lynch AS, Robertson GT (2008) Bacterial and fungal biofilm infections. Annu Rev Med 59: 415–428.
[3]
H？iby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O (2010) Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 35: 322–332.
[4]
Wagner C, H？nsch GM, Wentzensen A, Heppert V (2006) Implant-associated post-traumatic osteomyelitis. Bacterial biofilms and the immune defence as protagonists of the local inflammatory process. Unfallchirurg 109: 761–769.
[5]
Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, et al. (2010) Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 121: 458–477.
[6]
Mermel Leonard A, Allon M, Bouza E, Craven Donald E, Flynn P, et al. (2009) Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 49: 1–45.
[7]
Console G, Calabro C, Nardulli P, Digiuseppe F, Rucci A, et al. (2007) Clinical and economic effects of central venous catheters on oncology patient care. J Chemother 19: 309–314.
[8]
Scott RD (2009) The Direct Medical Costs of Healthcare-Associated Infections in U.S. Hospitals and the Benefits of Prevention. CDC 1–16.
[9]
Coenye T, Nelis HJ (2010) In vitro and in vivo model systems to study microbial biofilm formation. J Microbiol Methods 83: 89–105.
[10]
Donlan RM (2011) Biofilm elimination on intravascular catheters: important considerations for the infectious disease practitioner. Clin Infect Dis 52: 1038–1045.
[11]
Francolini I, Donelli G (2010) Prevention and control of biofilm based-medical device related infections. FEMS Immunology & Medical Microbiology 1–12.
[12]
Sim？es M (2011) Antimicrobial strategies effective against infectious bacterial biofilms. Curr Med Chem 18: 2129–2145.
[13]
Kadurugamuwa JL, Sin L, Albert E, Yu J, Francis K, et al. (2003) Direct continuous method for monitoring biofilm infection in a mouse model. Infection and Immunity 71: 882–890.
[14]
Vuong C, Kocianova S, Yu J, Kadurugamuwa Jagath L, Otto M (2008) Development of Real-Time In Vivo Imaging of Device-Related Staphylococcus epidermidis Infection in Mice and Influence of Animal Immune Status on Susceptibility to Infection. J Infect Dis 198: 258–261.
[15]
Wang R, Khan BA, Cheung GYC, Bach T-HL, Jameson-Lee M, et al. (2011) Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J Clin Invest 121: 238–248.
[16]
Cirioni O, Giacometti A, Ghiselli R, Dell'Acqua G, Orlando F, et al. (2006) RNAIII-inhibiting peptide significantly reduces bacterial load and enhances the effect of antibiotics in the treatment of central venous catheter-associated Staphylococcus aureus infections. J Infect Dis 193: 180–186.
[17]
Fernández-Hidalgo N, Gavaldà J, Almirante B, Martín M-T, Onrubia PL, et al. (2010) Evaluation of linezolid, vancomycin, gentamicin and ciprofloxacin in a rabbit model of antibiotic-lock technique for Staphylococcus aureus catheter-related infection. J Antimicrob Chemother 65: 525–530.
[18]
Rupp ME, Ulphani JS, Fey PD, Mack D (1999) Characterization of Staphylococcus epidermidis polysaccharide intercellular adhesin/hemagglutinin in the pathogenesis of intravascular catheter-associated infection in a rat model. Infection and Immunity 67: 2656–2659.
[19]
Van Praagh AD, Li T, Zhang S, Arya A, Chen L, et al. (2011) Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections. Antimicrobial agents and chemotherapy 55: 4081–4089.
[20]
Maki DG, Kluger DM, Crnich CJ (2006) The risk of bloodstream infection in adults with different intravascular devices: a systematic review of 200 published prospective studies. Mayo Clin Proc 81: 1159–1171.
[21]
Brun-Buisson C, Abrouk F, Legrand P, Huet Y, Larabi S, et al. (1987) Diagnosis of central venous catheter-related sepsis. Critical level of quantitative tip cultures. Arch Intern Med 147: 873–877.
[22]
Ramphal R, Balloy V, Jyot J, Verma A, Si-Tahar M, et al. (2008) Control of Pseudomonas aeruginosa in the lung requires the recognition of either lipopolysaccharide or flagellin. J Immunol 181: 586–592.
[23]
Bernier C, Gounon P, Le Bouguenec C (2002) Identification of an aggregative adhesion fimbria (AAF) type III-encoding operon in enteroaggregative Escherichia coli as a sensitive probe for detecting the AAF-encoding operon family. Infection and immunity 70: 4302–4311.
[24]
Foucault M-L, Thomas L, Goussard S, Branchini BR, Grillot-Courvalin C (2010) In vivo bioluminescence imaging for the study of intestinal colonization by Escherichia coli in mice. Applied and Environmental Microbiology 76: 264–274.
[25]
F？tkenheuer G, Buchheidt D, Cornely OA, Fuhr H-G, Karthaus M, et al. (2003) Central venous catheter (CVC)-related infections in neutropenic patients–guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 82: Suppl 2S149–157.
[26]
Tavares E, Maldonado R, Ojeda ML, Mi？ano FJ (2005) Circulating inflammatory mediators during start of fever in differential diagnosis of gram-negative and gram-positive infections in leukopenic rats. Clin Diagn Lab Immunol 12: 1085–1093.
[27]
Messing B, Peitra-Cohen S, Debure A, Beliah M, Bernier JJ (1988) Antibiotic-lock technique: a new approach to optimal therapy for catheter-related sepsis in home-parenteral nutrition patients. JPEN J Parenter Enteral Nutr 12: 185–189.
[28]
Niederhuber JE, Ensminger W, Gyves JW, Liepman M, Doan K, et al. (1982) Totally implanted venous and arterial access system to replace external catheters in cancer treatment. Surgery 92: 706–712.
[29]
Raad I (1998) Intravascular-catheter-related infections. Lancet 351: 893–898.
[30]
Kokai-Kun JF, Chanturiya T, Mond JJ (2009) Lysostaphin eradicates established Staphylococcus aureus biofilms in jugular vein catheterized mice. J Antimicrob Chemother 64: 94–100.
[31]
Lorenz U, Hüttinger C, Sch？fer T, Ziebuhr W, Thiede A, et al. (2008) The alternative sigma factor sigma B of Staphylococcus aureus modulates virulence in experimental central venous catheter-related infections. Microbes Infect 10: 217–223.
[32]
Kadurugamuwa JL, Francis KP (2008) Bioluminescent imaging of bacterial biofilm infections in vivo. Methods Mol Biol 431: 225–239.
[33]
Groeger JS, Lucas AB, Thaler HT, Friedlander-Klar H, Brown AE, et al. (1993) Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 119: 1168–1174.
[34]
Fallat ME, Gallinaro RN, Stover BH, Wilkerson S, Goldsmith LJ (1998) Central venous catheter bloodstream infections in the neonatal intensive care unit. Journal of Pediatric Surgery 33: 1383–1387.
[35]
CDC (1998) National Nosocomial Infections Surveillance (NNIS) System report, data summary from October 1986–April 1998, issued June 1998. American Journal of Infection Control 26: 522–533.
[36]
Chang L, Tsai J-S, Huang S-J, Shih C-C (2003) Evaluation of infectious complications of the implantable venous access system in a general oncologic population. Am J Infect Control 31: 34–39.
[37]
Friedman ND, Korman TM, Fairley CK, Franklin JC, Spelman DW (2002) Bacteraemia due to Stenotrophomonas maltophilia: an analysis of 45 episodes. J Infect 45: 47–53.
[38]
Hanna H, Afif C, Alakech B, Boktour M, Tarrand J, et al. (2004) Central venous catheter-related bacteremia due to gram-negative bacilli: significance of catheter removal in preventing relapse. Infect Control Hosp Epidemiol 25: 646–649.
[39]
Seifert H (1997) Catheter-related Infections. Catheter-related infections due to gram-negative bacilli. In: Seifert H, Jansen B, Farr BM, editors. New York: Marcel Dekker. pp. 255–284.
[40]
Astagneau P, Maugat S, Tran-Minh T, Douard M-C, Longuet P, et al. (1999) Long-term central venous catheter infection in HIV-infected and cancer patients: a multicenter cohort study. Infection control and hopsital epidemiology 20: 494–498.
[41]
Casey AL, Mermel LA, Nightingale P, Elliott TSJ (2008) Antimicrobial central venous catheters in adults: a systematic review and meta-analysis. Lancet Infect Dis 8: 763–776.
[42]
Darouiche RO, Berger DH, Khardori N, Robertson CS, Wall MJ, et al. (2005) Comparison of antimicrobial impregnation with tunneling of long-term central venous catheters: a randomized controlled trial. Ann Surg 242: 193–200.
[43]
del Pozo JL, Serrera A, Martinez-Cuesta A, Leiva J, Penades J, et al. (2006) Biofilm related infections: is there a place for conservative treatment of port-related bloodstream infections? Int J Artif Organs 29: 379–386.
[44]
Fernandez-Hidalgo N, Almirante B, Calleja R, Ruiz I, Planes AM, et al. (2006) Antibiotic-lock therapy for long-term intravascular catheter-related bacteraemia: results of an open, non-comparative study. J Antimicrob Chemother 57: 1172–1180.
[45]
Rijnders BJ, Van Wijngaerden E, Vandecasteele SJ, Stas M, Peetermans WE (2005) Treatment of long-term intravascular catheter-related bacteraemia with antibiotic lock: randomized, placebo-controlled trial. J Antimicrob Chemother 55: 90–94.
[46]
Fowler VG, Justice A, Moore C, Benjamin DK, Woods CW, et al. (2005) Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteremia. Clin Infect Dis 40: 695–703.
